[2] [2] HOY H, LYNCH T, BECK M. Surgical treatment of lung cancer［J］ Critical Care Nursing Clinics North America, 2019, 31(3): 303-313..

[4] [4] SYED Y Y. Anlotinib: first global approval［J］ . Drugs, 2018, 78(10): 1057-1062.

[5] [5] SHEN G, ZHENG F, REN D, et al. Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development［J］ . Journal of Hematology & Oncology, 2018, 11(1): 120.

[6] [6] BABINA I S, TURNER N C. Advances and challenges in target-ing FGFR signalling in cancer［J］ . Nature Reviews Cancer, 2017, 17(5): 318-332.

[7] [7] SZTURZ P, RAYMOND E, ABITBOL C, et al. Understanding c-MET signalling in squamous cell carcinoma of the head & neck［J］ . Criti-cal Reviews in Oncology Hematology, 2017, 111: 39-51.

[8] [8] HOXHAJ G, MANNING B D. The PI3K-AKT network at the in-terface of oncogenic signalling and cancer metabolism［J］ . Nature Reviews Cancer, 2020, 20(2): 74-88.

[9] [9] TAN A C. Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC)［J］ . Thorac Cancer, 2020, 11(3): 511-518.

[11] [11] ARENA S, SALATI M, SORGENTONI G, et al. Characterization of tumor-derived mesenchymal stem cells potentially differentiat-ing into cancer-associated fibroblasts in lung cancer［J］ . Clinical & Translational Oncology, 2018, 20(12): 1582-1591.

[14] [14] XIE C, WAN X, QUAN H, et al. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor［J］ . Cancer Science, 2018, 109(4): 1207-1219.

[15] [15] HE C, WU T, HAO Y. Anlotinib induces hepatocellular carcinoma apoptosis and inhibits proliferation via Erk and Akt pathway［J］ . Biochemical and Biophysical Research Commun, 2018, 503(4): 3093-3099.

[18] [18] YANG Y, GAO M, LIN Z, et al. DEK promoted EMT and angiogenesis through regulating PI3K/AKT/mTOR pathway in triple-negative breast cancer［J］ . Oncotarget, 2017, 8(58): 98708-98722.

[19] [19] RADEMACHER B L, MATKOWSKYJ K A, LACOUNT E D, et al. Topical application of a dual PI3K/mTOR inhibitor prevents anal carcinogenesis in a human papillomavirus mouse model of anal cancer［J］ . European Journal of Cancer Prevention, 2019, 28(6): 483-491.